Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 7/20 | 0.56 |
| ▸ | CMA1 | P23946 | 1/20 | 0.56 |
| ▸ | TYR | P14679 | 1/20 | 0.56 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.46 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.46 |
| ▸ | ITGAL | P20701 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28210442 | 0.98 | AHR (0.54) | AHRCMA1TYRENPP2CYP2A6 | |
| SCHEMBL295907 | 0.81 | AHR (0.56) | AHRCYP2A6GPR84TRPA1CA1 | |
| SCHEMBL5464492 | 0.78 | NPC1 (0.49) | AHRCMA1TYRENPP2CYP2A6 | |
| SCHEMBL2530865 | 0.73 | GPR84 (0.67) | AHRCMA1TYRENPP2CYP2A6 | |
| SCHEMBL5199321 | 0.73 | AHR (0.58) | AHRCMA1TYRENPP2CYP2A6 | |
| SCHEMBL5132372 | 0.71 | AHR (0.56) | AHRCMA1TYRENPP2CYP2A6 | |
| SCHEMBL566682 | 0.71 | AHR (0.56) | AHRCMA1TYRENPP2CYP2A6 | |
| SCHEMBL147423 | 0.71 | AHR (1.00) | AHRCMA1TYRENPP2CYP2A6 | |
| SCHEMBL275135 | 0.71 | AHR (0.56) | AHRCMA1TYRENPP2CYP2A6 | |
| SCHEMBL75475 | 0.71 | AHR (1.00) | AHRCMA1TYRENPP2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106995400-A | A kind of compound and its salt and its synthetic method | 湘潭大学 | 2017-08-01 | — | — | CN | claimed |
| CN-101495464-B | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA NV | 2014-03-05 | — | — | CN | claimed |
| CN-103396398-A | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA NV | 2013-11-20 | — | — | CN | claimed |
| EP-2585069-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | Janssen Pharmaceutica, N.V. (BE) | 2013-05-01 | — | — | EP | claimed |
| EP-1973886-B1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-27 | — | — | EP | claimed |
| WO-2012006004-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-12 | — | — | WO | claimed |
| US-20110319400-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA, NV (BE) | 2011-12-29 | — | — | US | claimed |
| EP-2385042-A1 | Prokineticin 1 receptor antagonists | Janssen Pharmaceutica N.V. (BE) | 2011-11-09 | — | — | EP | claimed |
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | claimed |
| US-8039028-B2 | Use of an extract of the orchid Vanda coerulea as a skin hydrating agent | LVMH REACHERCHE (FR) | 2011-10-18 | — | — | US | claimed |
| EP-2091929-A1 | AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS | The European Molecular Biology Laboratory (DE) | 2009-08-26 | — | — | EP | claimed |
| CN-101495464-A | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-29 | — | — | CN | claimed |
| CN-101405002-A | Prokineticin 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-08 | — | — | CN | claimed |
| US-20080287445-A1 | Prokineticin 2 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-20 | — | — | US | claimed |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-30 | — | — | US | claimed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | claimed |
| EP-1973886-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-10-01 | — | — | EP | claimed |
| WO-2007107352-A1 | AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS | THE EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2007-09-27 | — | — | WO | claimed |
| WO-2007079163-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | claimed |
| CN-1653050-A | Opioid and opioid-like compounds and uses thereof | JENKEN BIOSCIENCES INC (US) | 2005-08-10 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319400-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | PROKR1, OPRL1, PROKR2 | AHR 3416/4885CMA1 116/4885TYR 3447/4885 |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | PROKR1, PROKR2, GIPR | AHR 3334/4885CMA1 163/4885TYR 4419/4885 |
| US-20080287445-A1 | Prokineticin 2 receptor antagonists | PROKR2, PROKR1, GIPR | AHR 3408/4885CMA1 364/4885TYR 4611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.